What Happened?
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) fell 10.9% in the afternoon session after the company's disappointing full-year revenue guidance for 2026 overshadowed its otherwise solid first-quarter results.
While the diabetes technology company's first-quarter revenue of $247.2 million grew 5.5% year-over-year and its GAAP loss of $0.30 per share was better than analysts had feared, investors focused on the bleak outlook.
Tandem reconfirmed its full-year revenue guidance of $543 million at the midpoint, a figure that was nearly 50% below Wall Street's expectations. This significant downward revision in its forecast signaled major headwinds for the company, prompting a sharp sell-off in its shares despite the positive aspects of the quarterly report.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Tandem Diabetes’s shares are extremely volatile and have had 45 moves greater than 5% over the last year. But moves this big are rare even for Tandem Diabetes and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 3 months ago when the stock gained 30.2% on the news that the company reported better-than-expected fourth-quarter financial results.
The medical device maker posted quarterly sales of $290.4 million, a 15% increase year-on-year that surpassed analyst estimates. The company also recorded a much smaller-than-expected loss of just one cent per share. While this was a slight decline from the one-cent profit reported in the same quarter last year, it handily beat forecasts. Investors appeared to focus on the strong quarterly performance and improved operating margins, driving the stock higher despite the company issuing a 2026 sales forecast that was slightly below market expectations.
Tandem Diabetes is down 25.6% since the beginning of the year, and at $16.04 per share, it is trading 43.3% below its 52-week high of $28.26 from February 2026. Investors who bought $1,000 worth of Tandem Diabetes’s shares 5 years ago would now be looking at only $199.20.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
